A Pilot Study to Evaluate the Effects of Subcutaneously Administered Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor in Pediatric HIV-Infected Patients With Neutropenia Secondary to Azidothymidine

Inclusion Criteria Concurrent Medication: Allowed: * Zidovudine (AZT) on NIAID 86-C-175. Patients must have: * Diagnosis of perinatal or transfusion acquired AIDS or AIDS related complex. * Granulocytopenia (\< or = to 800 cells/mm3) associated with the administration of AZT on protocol NIAID 86-C-175. * Life expectancy \> 3 months. * Functioning indwelling central venous access device in place. Prior Medication: Allowed within 48 hours of study entry: * Prophylactic antibiotics. Exclusion Criteria Co-existing Condition: Patients with the following conditions or symptoms are excluded: * Critically ill or clinically unstable. * Significant, active opportunistic or other infection requiring specific drug therapy at time of study entry. * Ongoing IV alimentation. * Uncorrected nutritional deficiencies that may contribute to anemia and/or leukopenia. * Past history of or current evidence for any chronic hematologic disorder other than hemophilia A or B, anemia of chronic disease or anemia related to HIV infection. * Malignancy likely to require systemic treatment during study. Patients with the following are excluded: * Critically ill, clinically unstable, or with concomitant diseases listed in Patient Exclusion Co-existing Conditions. * Hypersensitivity to zidovudine (AZT) or any other nucleoside analog. Prior Medication: Excluded within 48 hours of study entry: * Antibiotics. * Excluded within 30 days of study entry: * Antiretroviral agents other than zidovudine (AZT). * Acyclovir. * Ganciclovir. * Any investigational drug. * Immunomodulating drugs. * Cytolytic chemotherapeutic agents. * Corticosteroids. * Immunoglobulin preparations. * Excluded within 4 months of study entry: * Suramin. Prior Treatment: Excluded within 6 months of study entry: * Bone marrow transplantation. * Excluded within 4 weeks of study entry: * Lymphocyte transfusions. * Radiation therapy.